Form 8-K - Current report:
SEC Accession No. 0000950170-24-059491
Filing Date
2024-05-14
Accepted
2024-05-14 16:02:13
Documents
13
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krro-20240514.htm   iXBRL 8-K 44148
2 EX-99.1 krro-ex99_1.htm EX-99.1 95283
3 GRAPHIC img174420225_0.jpg GRAPHIC 3576
  Complete submission text file 0000950170-24-059491.txt   283145

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT krro-20240514.xsd EX-101.SCH 32942
17 EXTRACTED XBRL INSTANCE DOCUMENT krro-20240514_htm.xml XML 5074
Mailing Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139 617-468-1999
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39062 | Film No.: 24944113
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)